This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

AMRI Burlington Contracted As Aseptic Fill Manufacturer For Market Introduction Of Excellagen® Wound Care Product

ALBANY, N.Y., June 5, 2012 /PRNewswire/ --  AMRI (NASDAQ: AMRI) announced today that its Burlington site was contracted by Cardium Therapeutics (NYSE MKT: CXM) and its subsidiary, Tissue Repair Company ("Cardium") to manufacture sterile pre-filled syringes in support of the U.S. introduction of Excellagen ® , a professional-use, formulated collagen-based product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. AMRI's highly collaborative approach to technical transfer enabled Cardium to meet its commercial introduction timeline and overall business needs.


Excellagen is a new, FDA-cleared, highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound-care management. Its unique high molecular weight bovine Type I collagen formulation is topically applied through easy-to-control, pre-filled, single use syringes. Excellagen is intended for physician use following debridement procedures, and is engineered to support a favorable wound healing environment for non-healing lower extremity ulcers in diabetic patients. Excellagen was introduced to the U.S. market by Cardium Therapeutics on March 30, 2012.

"We are pleased to be supporting Cardium's U.S. marketing introduction of Excellagen," said Thomas E. D'Ambra, Ph.D., Chairman, President and CEO of AMRI. "As a growing number of healthcare companies like Cardium face technically rigorous product manufacturing needs, we believe they will look to AMRI given our enhanced quality, proven experience, and scientific excellence to successfully address these challenges and ensure the highest manufacturing standards. We congratulate Cardium on the commercialization of Excellagen, a product that will address an unmet market need and provide a benefit to a growing patient population."

Dr. D'Ambra continued, "Supporting the Excellagen commercial market entry is a good illustration of further opportunities ahead and a validation of the market potential for AMRI's participation in the aseptic dosage form business."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs